ReviewJHEP reports : innovation in hepatology2025
"The alcohol-harm paradox": Understanding socioeconomic inequalities in liver disease.
Review in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Socioeconomic Inequalities in Receipt of Curative-Intent Treatment and Survival After Surveillance-Detected Hepatocellular Carcinoma: A Nationwide Cohort Study.Alimentary pharmacology & therapeutics · 2026Article
- Detection of congeners and contaminants in commercial and homemade alcoholic beverages under varying temperatures using metal-phenolic film-coated quartz crystal microbalances.Scientific reports · 2026Article
- The global epidemiology of alcohol-associated liver disease.Hepatology communications · 2026Review
- Alcohol use disorder: an Australian perspective on screening, diagnosis, treatment and prevention.Internal medicine journal · 2026Review
- Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study.EClinicalMedicine · 2026Article
- Legal blood alcohol concentration limits and alcohol-attributable traffic mortality rates: an analysis across 165 countries.EClinicalMedicine · 2026Article
- Gut microbiome in alcohol-associated liver disease: interactions and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Past-month alcohol use in relation to the COVID-19 lockdown in 13 Indian states and union territories: gender, socioeconomic status, and state alcohol policy differences.Frontiers in public health · 2026Article
- Call to action: integrating steatotic liver disease into public health strategies in Canada.Lancet regional health. Americas · 2025Review
- The hidden epidemic of alcohol-induced neurological and psychiatric mortality in the U. S. (1999-2023): trends and disparities.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alcohol-harm paradox (AHP) refers to the fact that people from lower socioeconomic groups experience higher rates of alcohol-related illness despite consuming the same or even lower amounts of alcohol than their more affluent counterparts. While differences in drinking patterns and associations with other risky behaviours partially explain the paradox, they do not fully account for the disparities in morbidity and mortality across socioeconomic groups. The existence of an alcohol-harm paradox in liver disease has been demonstrated in many countries worldwide. Recently, the COVID-19 pandemic further exacerbated these differences and led to an increase in alcohol intake and alcohol-related mortality among racial and ethnic minorities in the United States. Approaches to limit alcohol sales, through introduction of minimum unit pricing or taxation, have led to reductions in alcohol-related liver disease, particularly in socioeconomically deprived areas. Disparities in access to treatment of alcohol use disorder, liver disease and liver transplantation further contribute to the AHP. This review focuses on the AHP, its impact on liver disease and the multi-level strategy that will be required to curb this phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.